Kura Oncology posts EHA investor deck detailing ziftomenib AML clinical update

Kura Oncology, Inc.

Kura Oncology, Inc.

KURA

0.00
  • Kura Oncology highlighted KOMZIFTI (ziftomenib) FDA clearance for adult relapsed or refractory NPM1-mutated AML.
  • Reported early launch momentum, with plans to expand ziftomenib use toward up to 50% of AML patients.
  • Ziftomenib 600 mg with venetoclax/azacitidine in relapsed or refractory NPM1-mutated AML showed ORR 87% in venetoclax-naïve patients.
  • Venetoclax-experienced patients showed ORR 48%; median overall survival 7.4 months; median CRc duration of response 8.6 months.
  • Cash and investments totaled USD 580.8 million as of 3/31/26; additional USD 180 million in anticipated payments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.